Benign intracranial hypertension occurred in four young women taking tetracycline for acne; two were also taking vitamin A. In a fifth case a 14-year-old boy developed papilloedema after taking a short course of tetracycline for bronchitis. All symptoms disappeared soon after stopping the drugs, though in two cases the papilloedema persisted for many months.
Introduction
Tetracycline is a well-recognised cause of raised intracranial pressure in infancy,l 2 but few cases have been documented in adults. 3 Only two such cases have been reported from Australia, and both were in adolescent girls with acne. 4 6 Another cause of the syndrome is acute or long-term overdosage of vitamin A.6 7 We describe five young adults with benign intracranial hypertension associated with tetracycline. Four of them were women who had been taking the drug for acne, two of whom had also been taking vitamin A.
Case 1
A 19-year-old trainee nurse was admitted to this hospital in May 1972 after eight days of throbbing frontal headache, unsteadiness, nausea, and tinnitus. Physical examination showed only papilloedema. Fifteen months before she had been prescribed tetracycline and vitamin A for acne. She had continued to take the tetracycline until admission but had stopped the vitamin A after nine months. Results of routine blood biochemical tests and cell count were normal, as were an electroencephalogram, radioisotope brain scan, right carotid and vertebral angiograms, and pneumoencephalogram. With the patient laterally recumbent the lumbar cerebrospinal fluid pressure was 160 mm water; protein and sugar concentrations were 0-16 g/l and 5-3 ,umol/l (01 mg/100 ml) respectively, and microscopy showed 5 x 106 lymphocytes/l (5/mm3).
Dexamethasone, administered in decreasing dosage for four weeks, exacerbated the acne, and four days after discharge tetracycline was reinstituted. Papilloedema regressed and headache did not recur. The fundi were normal seven weeks after admission and had remained so when she was last seen 21 months later, still taking tetracycline. Despite stopping tetracycline on admission, instituting a course of dexamethasone and acetazolamide, and tapping the cerebrospinal fluid on three further occasions over six months, the papilloedema had remained unchanged in August 1975. Her symptoms had disappeared on the fifth day after admission.
Case 3
This 18-year-old woman had had recurrent otitis media in childhood, and a tympanoplasty had been performed in 1975. There was no further ear trouble. In January 1977 she began taking tetracycline 1 g daily for acne. In February vitamin A was added in a dose of 50 000 units on alternate days. About three weeks later she developed morning bitemporal headache, vomiting, and diplopia. Examination disclosed bilateral papilloedema, partial abducens palsies, and a minor conductive hearing loss on the left. An electroencephalogram contained a mild excess of non-focal and non-specific theta activity. Computed tomograms (CT scans) of brain and posterior fossa showed some enlargement of the interpeduncular cisterns but were otherwise normal. Cerebrospinal fluid pressure was 300 mm water; the protein concentration was 0 15 g/l, and there were no cells.
Tetracycline and vitaimin A were discontinued, and after two weeks of dexamethasone she was without symptoms or signs. The headache had subsided after the lumbar puncture on day 2 of her hospital stay.
Case 4
An 18-year-old woman was admitted in April 1978 with headache of a few weeks' duration, vomiting, and diplopia. Her medical history included acne and psoriasis, and for six months she had been taking the semisynthetic tetracycline minocycline 100 mg twice daily. Examination showed mild facial acne, bilateral papilloedema, and partial sixth-nerve palsies. A CT head scan was normal. At lumbar puncture the cerebrospinal fluid pressure was 140 mm water; protein concentration was 022 g/l; and glucose concentration and microscopical findings were normal.
Dexamethasone was given for three weeks, and the symptoms abated within a few days of admission. Minocycline was not reinstituted. Three weeks later she was well, without neurological abnormalities. 
Discussion
That four of these five patients were women agrees with the acknowledged predominance of women in adult cases of benign intracranial hypertension.8 All the women had acne. Two were taking tetracycline alone and two a combination of tetracycline and vitamin A. In all cases the drugs were prescribed in low dosage.
The delay from beginning the drug to the onset of symptoms ranged from a few days to 15 months. Despite reinstituting tetracycline in case 1 intracranial hypertension did not recur. In case 5 symptoms and signs reappeared 19 months after the initial illness despite abstinence from all drugs. In case 2 papilloedema remained for 14 months after withdrawal of tetracycline, despite disappearance of all symptoms of raised pressure.
The chronological relation between the development of intracranial hypertension and exposure to tetracycline may vary appreciably, and recurrence of symptoms many months after apparent recovery occurs in up to one-tenth of patients. 9 The prognosis, however, is good.8
Overdosage of vitamin A reportedly causes intracranial hypertension, but we could find no documented case after low dosage. Hence patients given tetracycline and vitamin A in combination may be at greater risk of raised intracranial pressure than patients given either drug alone.
In two of the patients the cerebrospinal fluid pressure measured at lumbar puncture was under 150 mm water. This would not exclude the diagnosis, however, as the intracranial pressure measured by an intraventricular catheter"0 may fluctuate widely in the disorder.
Although a drugmay be implicated as the cause on rare occasions (indomethacinll nalidixic acid,12 nitrofurantoin"3), in most cases the aetiology of the syndrome is not understood. Nevertheless, probably hormonal factors are present in cases associated with pregnancy, menarche, menstrual disturbances, oral contraceptives, obesity, hypoparathyroidism, and steroid treatment and withdrawal.
Computed tomography of the brain has greatly simplified the investigation and diagnosis of these patients. Probably none of our patients who were subjected to cerebral angiography or pneumoencephalography would today have been so managed.
The pathogenesis of this disorder remains a subject for speculation. Nevertheless, in each of our patients the cerebrospinal fluid protein concentration was at or below the lower limit of normal. This may reflect some disturbance in the secretory or filtratory function of the choroid plexus, leading to either an accumulation of cerebrospinal fluid 
Subjects, methods, and results
Thirty-five patients (16 men) with chronic discoid psoriasis (mean age 40-5 ±SD 13-8 years) were matched for sex, age, and smoking habits with healthy volunteers. None had clinical or biochemical evidence of liver, renal, or thyroid disease. None had used systemic or topical drugs in the previous three weeks.
Salivary clearance of antipyrine was measured after a dose of 600 mg (in gelatin capsules, bioavailability=0-96). Saliva (5 ml) was obtained at 3, 5, 8, 15, 24 , and 32 hours and antipyrine concentrations measured by gasliquid chromatography. Salivary clearance is the product of the eliminationrate constant (calculated by least squares regression analysis) and distribution volume (calculated by extrapolation).
Salivary clearance of antipyrine in the 17 patients who did not smoke (41-9±SEM 3-1 ml/min) was significantly (t=2-49, p<0025) less than that in the 17 non-smoking controls (51-9 ±2-9 ml/min). By contrast, salivary clearance was similar in the 18 patients who smoked (738 ±4 9 ml/min) and their controls (75-9 ±50 ml/min). Hence antipyrine clearance was only slightly lower (58-3 ±4-0 ml/min) in all 35 patients compared with all 35 controls (64-2 ±3-5 ml/min). In patients and controls antipyrine clearance was significantly greater in smokers than non-smokers and was linearly related to daily cigarette consumption (patients r=0-67, p<001; controls r=0 64, p <001-figure).
Comment
The results show that in non-smokers salivary antipyrine clearance was lower in the patients with psoriasis than the controls. As the patients and controls were closely matched, had no evidence of disease, and were not taking drugs, we conclude that the difference was due to the psoriasis itself.
Salivary antipyrine clearance corresponds with plasma clearance3 and is determined by the activity of hepatic mono-oxygenase(s). Our observations therefore suggest that the reduced epidermal activity of aryl hydrocarbon hydroxylase in clinically normal, lesionfree skin of patients with psoriasis' is part of a more widespread change in mono-oxygenase activity. This is further supported by our
